Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy(AIPAC-003) | terminated | Phase 2 / Phase 3 | 72 | Immutep S.A.S.INDUSTRY | 5 | Jul 30, 2026 |
| clinicaltrials |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors(PROFFi) | recruiting | Phase 2 | 164 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06445400 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 2 | 83 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732491 | Culmerciclib in HR+/HER2+ Advanced Breast Cancer | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | terminated | Phase 2 | 7 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02476786 | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | recruiting | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04243616 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer(CemiHALT) | active not recruiting | Phase 2 | 36 | Medical College of WisconsinOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer(ALISCA-Breast1) | recruiting | Phase 2 | 225 | Puma Biotechnology, Inc.INDUSTRY | 3 | Jul 27, 2026 | clinicaltrials |
| NCT06604858 | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer(TELESCOPE) | completed | Phase 2 | 31 | MedSIROTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729046 | Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02252887 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02942355 | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC(ETNA) | recruiting | Phase 2 | 354 | UNICANCEROTHER | 2 | Jul 24, 2026 | clinicaltrials |
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases(BERLIN) | not yet recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726342 | SMP-656 for HER2-Positive Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Chengdu SciMount Pharmatech Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06026657 | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Margaret Gatti-MaysOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06471205 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07593976 | Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer(GATHER) | recruiting | Phase 2 | 42 | Centre Henri BecquerelOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | not yet recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | active not recruiting | Phase 1 / Phase 2 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03546686 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | active not recruiting | Phase 2 | 51 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07591090 | A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | recruiting | Phase 2 | 200 | AkesoINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | recruiting | Phase 2 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04537286 | First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients | completed | Phase 2 | 90 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05297617 | Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk(LESS) | recruiting | Phase 2 | 696 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer(ELONA) | terminated | Phase 1 / Phase 2 | 4 | Context Therapeutics Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.(HEROES) | recruiting | Phase 2 | 170 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT03414658 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | active not recruiting | Phase 2 | 100 | Adrienne G. WaksOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04758780 | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer(OPALESCENCE) | completed | Phase 2 | 12 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04230109 | Sacituzumab Govitecan In TNBC(NeoSTAR) | recruiting | Phase 2 | 239 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04542135 | Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | completed | Phase 2 | 61 | Alison StopeckOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07661927 | Skipping Hormone Therapy in Low-Risk Early Breast Cancer(NoELA) | recruiting | Phase 2 | 700 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04115306 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer(Dauntless-1) | active not recruiting | Phase 1 / Phase 2 | 61 | Phoenix Molecular DesignsINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06640881 | Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial(REPEAT) | recruiting | Phase 2 | 25 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708194 | Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | recruiting | Phase 1 / Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06465368 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | completed | Phase 2 | 121 | PfizerINDUSTRY | 13 | Jul 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2026source: clinicaltrials